Germany will become the first EU country to launch Novo Nordisk's oral Wegovy semaglutide pill, with rollout scheduled for September after European Commission marketing authorisation in July. In a 64-week trial the pill produced about 33 lb of average weight loss, about 14% of starting body weight,…
Germany will become the first European Union country to launch Novo Nordisk's oral Wegovy semaglutide pill , with the rollout scheduled for September. The European Commission granted marketing authorisation for the pill in July, and Novo Nordisk disclosed the timing during an earnings call. The September date makes Germany the first EU launch market for an oral GLP-1 drug, and the first test of whether a GLP-1 peptide can reach patients in Europe without an injectable device.
The UK became the first European country to approve the pill in June, and the drug is already available from UK online pharmacies. In the United States, the Wegovy pill and Eli Lilly's oral GLP-1 drug orforglipron , marketed as Foundayo , already have US approval. Foundayo has not yet entered the European market, so the first EU launch will belong to Novo Nordisk's peptide.
The commercial argument for the pill rests on three attributes: it is more palatable than an injection, needs no refrigeration, and costs less. Novo Nordisk expects that combination to markedly expand GLP-1 use in Europe by drawing in people who will not take injectable therapy. The drug's current approved uses are weight loss and chronic weight management, and potential additional benefits are being researched.
The September German rollout is the first of several planned waves. "We look forward to launching the Wegovy pill in select countries before the end of the year," a spokesperson for Novo Nordisk said. The spokesperson did not identify which countries would receive the pill before the year-end, so the near-term geography beyond Germany is unspecified.
The company expects the pill to become available in more EU countries in the second half of 2026. That projection is an expectation rather than a confirmed schedule, and no country-by-country plan has been published. The announcement also did not state the year of the European Commission authorisation or of the German launch, although the sequence is explicit: UK approval in June, EU authorisation in July, German rollout in September.
The UK's experience previews how access will work elsewhere. The pill won UK approval in June and is already sold through online pharmacies, but the National Institute for Health and Care Excellence NICE is still assessing it for NHS use. Authorisation and funding are separate decisions, and the German launch does not by itself determine when patients in other member states will get the drug or on what terms.
The efficacy evidence comes from a 64-week trial comparing the Wegovy pill, taken alongside a reduced-calorie diet and increased physical activity, against placebo. The trial enrolled adults living with obesity, or with overweight and at least one weight-related medical problem. The results were reported both as absolute weight loss in pounds and as a percentage of starting body weight.
Adults in the pill group lost about 33 lb on average, or about 14% of starting body weight. The placebo group lost about 6 lb, or about 2.4%. Mean starting weights were similar: 235 lb in the pill group and 231 lb in the placebo group. The two metrics are internally consistent: 14% of 235 lb is about 33 lb, and 2.4% of 231 lb is about 5.5 lb, in line with the reported 6 lb for placebo. Reporting weight loss as a percentage of starting weight is the standard way to compare across trials because it controls for baseline differences; the near-identical starting weights here make the direct comparison clean.
The reported side-effects were nausea, diarrhoea, constipation and fatigue. For a chronic weight-management drug, tolerability is a central determinant of whether people stay on treatment long enough to benefit, and the announcement itself flags that these effects may affect how long people continue.
What the announcement does not include matters as much as what it reports. The sample size is not stated, and group assignment and blinding are not described. The available description supports a conclusion that the pill produced weight loss in this population under lifestyle conditions, but it cannot support conclusions about durability beyond 64 weeks, cardiovascular outcomes, or comparative performance against injectable GLP-1 therapy. Those would require the full trial publication and separate outcome studies.
The European Commission granted marketing authorisation for the Wegovy semaglutide pill in July. A Commission marketing authorisation is valid across the European Union as a single approval covering all member states, and it is the legal basis for the drug to be placed on the market in the EU. The authorisation covers the current indications: weight loss and chronic weight management.
The authorisation does not dictate when each country starts selling the drug. Launch sequencing is a commercial decision, and Novo Nordisk has chosen Germany first, with more EU countries expected in the second half of 2026. National pricing and reimbursement arrangements sit outside the authorisation system, which is why a single EU approval can still result in very different availability across member states.
The UK case illustrates the distinction. The UK approved the pill in June, becoming the first European country to do so, and the drug is already available from online pharmacies in the UK. But NICE, which evaluates cost-effectiveness for the National Health Service NHS , is still reviewing the pill. A marketing authorisation establishes that a drug can be sold; a NICE recommendation determines whether the NHS will fund it. Between those two decisions sits the difference between approval on paper and access in practice.
For clinicians and patients, the relevant regulatory question is therefore not only whether a drug is authorised but when and on what terms it reaches them. Germany's September rollout will be the first EU test of that question for an oral GLP-1 peptide.
Semaglutide is a peptide agonist of the glucagon-like peptide 1 GLP-1 receptor . GLP-1 is an incretin hormone secreted by intestinal L cells in response to food. It potentiates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and acts on appetite circuits in the central nervous system. A GLP-1 receptor agonist such as semaglutide amplifies those signals, which is how a single molecule produces coordinated effects on glucose control, gut motility, and food intake.
Peptides are hard to deliver orally. The gastrointestinal tract is adapted to break down proteins, and peptide drugs in general have poor stability in gastric acid and poor permeability across the intestinal wall. That is why GLP-1 receptor agonists have historically been injectable. An oral peptide formulation must protect the drug through the stomach and facilitate its absorption, so the innovation in the Wegovy pill is as much formulation science as pharmacology. Oral semaglutide marks a shift toward non-injectable delivery of GLP-1 peptides, with direct implications for how these drugs are made, stored and taken.
The practical consequences flow from that shift. An oral option removes the injection barrier for people eligible for weight management who avoid injectable drugs. It changes logistics: the pill needs no refrigeration, which simplifies distribution and storage. And it changes cost, with the company saying the pill costs less. Each of those attributes is expected to expand the pool of GLP-1 users in Europe.
The 64-week efficacy and side-effect data now serve as a benchmark for oral versus injectable outcomes. The reported side-effects, nausea, diarrhoea, constipation and fatigue, are consistent with GLP-1 receptor stimulation in the gut and brain, and they are the type of effects most likely to determine persistence. How the oral peptide compares with injectable semaglutide, and with Eli Lilly's orally delivered small-molecule GLP-1 agonist orforglipron, is the comparison that will define this market.
The Peptide Atlas registry file for semaglutide https://peptideatlas.co/peptides/semaglutide lists 668 registered clinical trials. The phase breakdown in the file shows 4 Phase 2 trials, 4 Phase 4 trials, and 1 Phase 3 trial, and the status breakdown shows 10 trials currently recruiting. The phase distribution points to a programme that has moved past the initial registration studies and into mechanism-testing and implementation questions.
The recruiting trials show how far the research agenda has expanded beyond obesity:
The indexed literature in the Peptide Atlas database stands at 197 PubMed papers on semaglutide. Recent entries track the same expansion: a systematic review and meta-analysis of long-term safety and renal outcomes of semaglutide in non-diabetic obesity with chronic kidney disease or hypertension PMID 42340790, Clin Ter, July 2026 ; a systematic review and meta-analysis of weight-lowering drugs and natural female fertility PMID 42307450, Clin Obes, July 2026 ; a randomised trial of semaglutide and effort-based decision-making in major depressive disorder PMID 42054055, JAMA Psychiatry, July 2026 ; the STRIDE trial of semaglutide in peripheral artery disease and diabetes by baseline disease severity and age PMID 41780559, European Heart Journal, July 2026 ; and a scoping review of the risk of retinal vascular events in patients using semaglutide PMID 42348481, Ophthalmologica, June 2026 . The list spans benefit and safety, psychiatry and vascular medicine, which is what a literature base looks like for a drug class being tested across many populations.
The orforglipron file https://peptideatlas.co/peptides/orforglipron is smaller: 0 registered clinical trials on file and 8 indexed PubMed papers. The most consequential paper is ACHIEVE-3 PMID 41765029, Lancet, March 2026 , a multinational, multicentre, non-inferiority , open-label, randomised phase 3 trial comparing once-daily oral orforglipron with oral semaglutide in adults with type 2 diabetes. A separate meta-analysis PMID 41715239, February 2026 has assessed the efficacy and safety of orforglipron, which the paper describes as an oral small-molecule GLP-1 receptor agonist , on cardiometabolic outcomes. The contrast matters: semaglutide is a peptide whose oral delivery depends on formulation, while orforglipron is a small molecule that can be dosed orally without that constraint. Two chemical strategies are converging on the same receptor.
Third-party laboratory testing in the Peptide Atlas file shows 8 purity tests for semaglutide, with the highest observed purity at 99.979%. At a moment when demand for GLP-1 peptides is scaling rapidly, independent purity data give formulators and purchasers a quality reference point that sits alongside the clinical and registry datasets.
For…
Peptides referenced: Semaglutide, Orforglipron, Glucagon, GLP-1.
Related reading: More Than 150 Deaths Reported After Weight Loss Drug Use, Hers Adds an AI Tool to Help Women Navigate Weight Loss and GLP-1 Use, Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs, Inside CVS Health's GLP-1 Push and Earnings Beat.